Proactive Investors - Run By Investors For Investors

ANGLE’s Parsortix liquid biopsy getting lots of exposure at world’s biggest cancer conference

Several ANGLE customers have been showcasing Parsortix at the American Association for Cancer Research conference in Atlanta
AACR is the world’s oldest and largest cancer research conference

ANGLE PLC’s (LON:AGL) Parsortix cancer detection system has been showcased by a number of customers at the world’s largest cancer research conference in Atlanta, US.

The University of Athens, Northwestern University and the National Tumour Institute of Milan all presented posters featuring Parsortix at the American Association for Cancer Research (AACR) conference.

Work by the University of Athens was particularly important, ANGLE said, as it demonstrated the “superior performance” of Parsortix in head and neck squamous cell carcinoma (HNSCC) versus antibody-based approaches.

READ: ANGLE’s Parsortix liquid biopsy proving to be more than just a cancer detection device

Several cancer drugs, including Bristol Myers-Squibb’s Opdivo and Merck’s Keytruda, work best in patients with high levels of PD-L1 expression.

In the UoA’s studies, Parsortix was found to be twice as effective at identifying patients with PD-L1 expression.

From a group of 50, Parsortix identified nine with PD-L1 expression whereas the antibody-based test only identified four.

Around one in five patients typically respond to PD-L1 immunotherapies so the Parsortix result was consistent with expected detection levels.

“The multiple poster presentations by ANGLE and its customers at AACR demonstrate new potential applications for ANGLE's Parsortix system and further builds the third-party evidence that Parsortix is a market-leading CTC liquid biopsy solution,” said chief executive Andrew Newland.

“The successful detection of PD-L1 in head and neck cancer opens the potential for collaboration with leading pharma companies with FDA cleared immunotherapy drugs.”

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use